# Pacira BioSciences, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Pacira BioSciences, Inc.).

## Overview

Pacira BioSciences is a U.S.-based biopharmaceutical company focused on non-opioid pain management products. Its portfolio includes EXPAREL, ZILRETTA, and iovera°, along with earlier-stage programs and acquired technologies that extend its presence in pain and musculoskeletal care.

## Products & services

• EXPAREL liposomal bupivacaine for postsurgical pain
• ZILRETTA extended-release injectable for knee OA pain
• iovera° cryoneurolysis system for nerve-based pain relief
• Bupivacaine liposome injectable suspension for veterinary use
• Pipeline programs from GQ Bio and other acquired assets

- **EXPAREL** (79%) — Liposomal bupivacaine injectable used for postsurgical pain control.
- **ZILRETTA** (16%) — Extended-release corticosteroid injection for knee osteoarthritis pain.
- **iovera°** (3%) — Cryoneurolysis system that temporarily disrupts peripheral nerves to reduce pain.
- **Other product sales** (1%) — Veterinary bupivacaine liposome sales and related product revenue.
- **Royalty and collaborative revenue** (1%) — Royalties and licensing-related revenue tied to veterinary use and collaborations.

- EXPAREL liposomal bupivacaine for postsurgical pain
- ZILRETTA extended-release injectable for knee OA pain
- iovera° cryoneurolysis system for nerve-based pain relief
- Bupivacaine liposome injectable suspension for veterinary use
- Pipeline programs from GQ Bio and other acquired assets

## Customers

Pacira sells primarily into healthcare channels that use pain-management therapies in surgical and orthopedic settings. Its products are bought by hospitals, ambulatory surgery centers, physicians, and other clinical providers that need non-opioid options for perioperative and musculoskeletal pain. The company also has a smaller veterinary-related revenue stream through licensed and product sales.

- **Hospitals and health systems** (primary) — Buy EXPAREL for postsurgical pain protocols and formulary use in inpatient and outpatient procedures.
- **Ambulatory surgery centers** (primary) — Use EXPAREL and related pain products to support same-day procedures and recovery.
- **Orthopedic and pain practices** (secondary) — Buy ZILRETTA and iovera° for knee osteoarthritis and nerve-based pain treatment.
- **Veterinary partners and distributors** (emerging) — Purchase or license bupivacaine liposome products for animal health applications.

- Hospitals and health systems using EXPAREL in surgical care
- Ambulatory surgery centers seeking non-opioid pain control
- Orthopedic and pain specialists using ZILRETTA and iovera°
- Clinical providers that value reimbursement and ease of use
- Veterinary channel customers for bupivacaine liposome products

## Geography

Pacira is headquartered in Brisbane, California and operates through a U.S. commercial base with manufacturing and development activities in the United States and the United Kingdom. Its marketed products are sold in the U.S., while EXPAREL and iovera° also have presence in the E.U. and the U.K., and iovera° is additionally sold in Canada. Geography matters because the company depends heavily on U.S. reimbursement and regulatory access, while its non-U.S. footprint is narrower and more selective.

- Headquartered in Brisbane, California
- Core commercial market is the United States
- EXPAREL is sold in the U.S., E.U., and U.K.
- iovera° is sold in the U.S., Canada, and E.U.
- Manufacturing capacity includes San Diego and Swindon, U.K.

## Strategy

Pacira’s strategy centers on defending and expanding its core pain-management portfolio, especially EXPAREL and ZILRETTA, through commercialization, market access, and reimbursement efforts. It is also building optionality through acquired technologies and pipeline assets, including GQ Bio, while maintaining manufacturing and operational capabilities that support supply reliability and product scale.

- **Expand core product adoption** (short-term) — EXPAREL and ZILRETTA are the main revenue engines, so deeper penetration drives the business.
- **Strengthen non-opioid pain franchise** (medium-term) — A broader portfolio reduces reliance on a single product and supports cross-selling.
- **Improve manufacturing and supply chain execution** (medium-term) — Reliable production and distribution are essential for a specialty pharmaceutical business.

- Grow EXPAREL adoption in surgical pain protocols
- Support ZILRETTA and iovera° commercialization in target specialties
- Invest in market access, reimbursement, and physician education
- Use acquisitions to add pipeline assets and platform technology
- Improve manufacturing efficiency and supply reliability

## Risks

Pacira is highly dependent on a small number of products, especially EXPAREL, so any loss of market share, pricing pressure, or reimbursement disruption can have an outsized effect. The business also faces patent, regulatory, and product-safety risk typical of specialty pharmaceuticals, along with execution risk tied to third-party manufacturing, distribution, and commercialization.

- **Dependence on EXPAREL commercialization** [high] — EXPAREL is the largest revenue contributor, so demand or access weakness would materially affect results.
- **Patent expiry and generic competition** [high] — The active ingredient in EXPAREL is off-patent, and competitors can challenge formulation protection.
- **Regulatory and product-safety actions** [high] — Adverse events or labeling concerns can trigger warnings, restrictions, or market withdrawal.
- **Third-party manufacturing and logistics dependence** [medium] — Key manufacturing, warehousing, and distribution functions are outsourced.

- Heavy dependence on EXPAREL and ZILRETTA revenue
- Patent challenges and generic competition for bupivacaine products
- FDA and other regulatory oversight of drugs and devices
- Product safety or labeling issues could restrict use
- Third-party manufacturing and distribution create supply risk

## Accounting

Pacira’s reported results are sensitive to revenue recognition for product sales, allowances, and collaborative/royalty arrangements, which can shift with order timing and payer deductions. Investors should also watch goodwill and intangible asset accounting, contingent consideration from acquisitions, and valuation judgments tied to pipeline assets and impairment testing.

- **Revenue recognition and sales allowances** — Allowance accruals directly affect reported revenue and receivables.
- **Goodwill impairment** — Impairment charges can be large and non-cash.
- **Contingent consideration** — Fair value changes flow through earnings.
- **Intangible asset valuation** — Amortization and impairment affect operating results.

- Revenue recognition for product sales and royalty streams
- Sales allowances, rebates, chargebacks, and returns reserves
- Goodwill and intangible asset impairment testing
- Contingent consideration from acquisitions
- Valuation of pipeline assets and fair value estimates

---

*Last updated: 2026-04-29T04:47:30.290104+00:00*